Status:
COMPLETED
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
Lead Sponsor:
University of Cologne
Conditions:
Hodgkin Disease
Non-Hodgkin Lymphoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
This study investigates whether the prophylactic use of moxifloxacin during high-dose chemotherapy followed by autologous stem cell transplantation reduces the incidence of clinically significant bact...
Detailed Description
Because fluoroquinolones have broad antimicrobial coverage, bactericidal activity, high tissue concentrations, oral bioavailability and adequate tolerability and safety profiles, they are ideal candid...
Eligibility Criteria
Inclusion
- High-dose chemotherapy followed by peripheral autologous stem cell transplantation
- Underlying disease: Hodgkin Disease, non-Hodgkin-lymphoma, multiple myeloma or solid tumor
Exclusion
- Allogenic stem cell transplantation
- Aplastic anemia
- Antibiotic treatment within seven days prior to randomization
- Signs and symptoms of current infection
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00398411
Start Date
October 1 2006
End Date
December 1 2008
Last Update
June 29 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinikum der Universität zu Köln
Cologne, Germany, 50924